Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Clinical evidence

BOND-003 cohort C

77 evidence topics · 22 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Treatment courses
CourseSchedule
Induction“Weekly x 6”
Maintenance, year 1“Weekly x 3 Q3M for Year 1”
Maintenance, years 2 to 3“Weekly x 3 Q6M for Year 2-3”
Second induction“Weekly x 6 for non-responders”
Study outcomes
Rationale for using complete response at any time as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics and disease characteristics, safety population
Characteristicn or value%
Male“83”“74.1”
Female“29”“25.9”
Age, mean (SD), years“72.9 (9.19)”
Age, median (range), years“74.0 (43-90)”
Age under 65 years“19”“17.0”
Age 65 to under 75 years“43”“38.4”
Age 75 years or older“50”“44.6”
Prior BCG instillations, median (range)“12 (7 – 66)”
CIS with high-grade Ta/T1“22”“19.6”
CIS alone“90”“80.4”
At least 1 prior therapy other than BCG“53”“47.3”
Serial adjuvant chemotherapy“34”“30.4”
Systemic immunotherapy“7”“6.3”
ECOG performance status, January 2025 data cutoff
Efficacy results
Complete response at 12 and 24 months, June 23, 2025 cutoff
LandmarkCR rate (95% CI)Participants in CRCR by Kaplan-Meier estimate (95% CI)
12 months“46.4% (36.9, 56.1)”“51 out of 110 patients”“50.7% (40.9, 59.8)”
24 months“41.8% (32.5, 51.6)”“46 out of 110”“42.4% (32.7, 51.7)”
Radical cystectomy: timing and pathologic stage
MeasureValue
Cystectomy any time after first recurrence, n (%)“18 (16.4%)”
Cystectomy within the first year of recurrence, n (%)“17 (15.5%)”
Weeks from recurrence or progression to cystectomy, median (Q1, Q3)“20.0 (14.4, 26.7)”
Stage T0, n (%)“1 (0.9)”
Stage CIS, n (%)“9 (8.2)”
Stage HG Ta, n (%)“1 (0.9)”
Stage T1, n (%)“4 (3.6)”
Stage T2A, n (%)“1 (0.9)”
Stage T2B, n (%)“1 (0.9)”
Stage N2, n (%)“1 (0.9)”
Participants with T0 or NMIBC at cystectomy“15/18 (83.3%) were T0 or NMIBC”
Cystectomy-free and progression-free rates at 24 months in a 2026 translational presentation
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-related adverse events in more than 10% of participants, June 23, 2025 cutoff
Preferred term (MedDRA v.26.1)Any grade, n (%)Grade 3 or higher, n (%)
At least 1 treatment-related adverse event“71 (63.4%)”“0 (0)”
Bladder spasm“28 (25.0%)”“0 (0)”
Pollakiuria“25 (22.3%)”“0 (0)”
Urgency“23 (20.5%)”“0 (0)”
Dysuria“21 (18.8%)”“0 (0)”
Hematuria“15 (13.4%)”“0 (0)”
Study limitations
Summary: limitations of the BOND-003 Cohort C evidence
  • Design: Cohort C is a single-arm, open-label trial with no concurrent control. The FDA 2024 draft guidance states that time-to-event endpoints are “uninterpretable in a single-arm trial” and that the lack of a comparator arm makes attributing adverse events difficult; cystectomy-free survival, progression-free survival, and duration of response therefore have no comparator in this trial. The FDA 2018 guidance states that patient and provider preferences “can confound the interpretation” of cystectomy delay, particularly in single-arm trials.
  • Primary endpoint: complete response at any time includes participants with persistent disease who underwent repeat induction treatment, which a later trial of another agent did not permit. At the June 23, 2025 cutoff, 83 of 110 participants (75.5%) had a complete response at any time, while landmark complete response rates were 46.4% (51 of 110) at 12 months and 41.8% (46 of 110) at 24 months.
  • Populations: 115 participants were enrolled, 112 were treated and form the safety population, and 110 who completed the 3-month assessment form the efficacy population. Eligibility required pathologically confirmed BCG-unresponsive CIS, ECOG performance status 0 to 2, and medical ineligibility for, or refusal of, radical cystectomy; prior systemic treatment for bladder cancer other than checkpoint inhibitors was excluded.
  • Sources: the peer-reviewed report is available only as an abstract in the sources read, and most results beyond the abstract (12-month and 24-month landmark rates, duration of response, cystectomy outcomes, subgroups) come from company-sponsored congress presentations, press releases, and filings. The trial was funded by CG Oncology. The prespecified statistical threshold for the primary endpoint was not found in the public sources read; the company states that the trial “met its primary endpoint with statistical significance”.
  • Figures that differ between documents for the same June 23, 2025 cutoff: duration of response at 12 and 24 months of 64.1% and 58.3% (September 2025 press release) against 64.2% and 60.1% (2026 press release and presentation); freedom from progression to muscle-invasive disease of 96.4% (106 of 110) against 96.6%; a lower 95% confidence bound for the 12-month landmark of 36.9% against 36.8%; 24-month cystectomy-free survival of 81.3% against 85% in a translational presentation; and the second serious treatment-related adverse event named as clot retention in a 2026 company presentation and the Form 10-K and as urinary bladder haemorrhage in the publication.
  • Dose: the publication states a dose of “1 × 1012 viral particles per 0·8 mL”, and the company annual report states “1x1012 VPs per milliliter”.
  • Applicability: Cohort C used a five-step instillation process that included saline and DDM washes; the company states that all later studies use a two-step process. No health-related quality-of-life or patient-reported outcome results were found.